BACKGROUND: The epidemics of food insecurity, malnutrition, and human immunodeficiency virus (HIV) frequently overlap. HIV treatment programs increasingly provide nutrient-dense ready-to-use supplementary foods (RUSFs) to patients living with HIV and food insecurity, but in the absence of wasting, it is not known if RUSF confers benefit above less costly food commodities. METHODS: We performed a randomized trial in rural Haiti comparing an RUSF with less costly corn-soy blendplus (CSB+) as a monthly supplement to patients with HIV infection who were on antiretroviral therapy (ART) <24 months prior to study start. We compared 6- and 12-month outcomes by ration type in terms of immunologic response, body mass index (BMI), adherence to ART, general health quality of life, household food insecurity, and household wealth. RESULTS: A cohort of 524 patients with HIV receiving ART was randomized and followed over time. Median CD4 cell count at baseline was 339 cells/µL (interquartile range [IQR], 197-475 cells/µL) for the CSB+ group, and 341 cells/µL (IQR, 213-464/µL) for the RUSF group. Measured outcomes improved from baseline over time, but there were no statistically significant differences in change for BMI, household wealth index, hunger, general health perception score, or adherence to ART by ration type at 6 or 12 months. The RUSF group had higher CD4 count at 12 months, but this was also not statistically significant. CONCLUSIONS: In 12 months of follow-up, there was no statistically significant difference in outcomes between those receiving RUSF-based compared with CSB+-based rations in a cohort of HIV-infected adults on ART in rural Haiti.
RCT Entities:
BACKGROUND: The epidemics of food insecurity, malnutrition, and human immunodeficiency virus (HIV) frequently overlap. HIV treatment programs increasingly provide nutrient-dense ready-to-use supplementary foods (RUSFs) to patients living with HIV and food insecurity, but in the absence of wasting, it is not known if RUSF confers benefit above less costly food commodities. METHODS: We performed a randomized trial in rural Haiti comparing an RUSF with less costly corn-soy blend plus (CSB+) as a monthly supplement to patients with HIV infection who were on antiretroviral therapy (ART) <24 months prior to study start. We compared 6- and 12-month outcomes by ration type in terms of immunologic response, body mass index (BMI), adherence to ART, general health quality of life, household food insecurity, and household wealth. RESULTS: A cohort of 524 patients with HIV receiving ART was randomized and followed over time. Median CD4 cell count at baseline was 339 cells/µL (interquartile range [IQR], 197-475 cells/µL) for the CSB+ group, and 341 cells/µL (IQR, 213-464/µL) for the RUSF group. Measured outcomes improved from baseline over time, but there were no statistically significant differences in change for BMI, household wealth index, hunger, general health perception score, or adherence to ART by ration type at 6 or 12 months. The RUSF group had higher CD4 count at 12 months, but this was also not statistically significant. CONCLUSIONS: In 12 months of follow-up, there was no statistically significant difference in outcomes between those receiving RUSF-based compared with CSB+-based rations in a cohort of HIV-infected adults on ART in rural Haiti.
Authors: R H Clark; G Feleke; M Din; T Yasmin; G Singh; F A Khan; J A Rathmacher Journal: JPEN J Parenter Enteral Nutr Date: 2000 May-Jun Impact factor: 4.016
Authors: Barry E Hurwitz; Johanna R Klaus; Maria M Llabre; Alex Gonzalez; Peter J Lawrence; Kevin J Maher; Jeffrey M Greeson; Marianna K Baum; Gail Shor-Posner; Jay S Skyler; Neil Schneiderman Journal: Arch Intern Med Date: 2007-01-22
Authors: B Ledergerber; M Egger; V Erard; R Weber; B Hirschel; H Furrer; M Battegay; P Vernazza; E Bernasconi; M Opravil; D Kaufmann; P Sudre; P Francioli; A Telenti Journal: JAMA Date: 1999-12-15 Impact factor: 56.272
Authors: Matthias Egger; Margaret May; Geneviève Chêne; Andrew N Phillips; Bruno Ledergerber; François Dabis; Dominique Costagliola; Antonella D'Arminio Monforte; Frank de Wolf; Peter Reiss; Jens D Lundgren; Amy C Justice; Schlomo Staszewski; Catherine Leport; Robert S Hogg; Caroline A Sabin; M John Gill; Bernd Salzberger; Jonathan A C Sterne Journal: Lancet Date: 2002-07-13 Impact factor: 79.321
Authors: Sheri D Weiser; Edward A Frongillo; Kathleen Ragland; Robert S Hogg; Elise D Riley; David R Bangsberg Journal: J Gen Intern Med Date: 2008-10-25 Impact factor: 5.128
Authors: Ronald A Cantrell; Moses Sinkala; Karen Megazinni; Sibi Lawson-Marriott; Sierra Washington; Benjamin H Chi; Bushimbwa Tambatamba-Chapula; Jens Levy; Elizabeth M Stringer; Lloyd Mulenga; Jeffrey S A Stringer Journal: J Acquir Immune Defic Syndr Date: 2008-10-01 Impact factor: 3.731
Authors: Aaron Richterman; Fernet Leandre; J Gregory Jerome; Alexander C Tsai; Louise C Ivers Journal: Open Forum Infect Dis Date: 2020-08-11 Impact factor: 3.835
Authors: Catherine A Koss; Paul Natureeba; Dalsone Kwarisiima; Mike Ogena; Tamara D Clark; Peter Olwoch; Deborah Cohan; Jaffer Okiring; Edwin D Charlebois; Moses R Kamya; Diane V Havlir Journal: J Acquir Immune Defic Syndr Date: 2017-03-01 Impact factor: 3.731
Authors: Anna Agape Minja; Elysia Larson; Zenaice Aloyce; Ricardo Araya; Anna Kaale; Sylvia F Kaaya; Janeth Kamala; Muhummed Nadeem Kasmani; Amina Komba; Angelina Mwimba; Fileuka Ngakongwa; Hellen Siril; Mary C Smith Fawzi; Magreat Somba; Christopher R Sudfeld; Caleb J Figge Journal: AIDS Care Date: 2022-03-11
Authors: Anne G Beckett; Debbie Humphries; J Gregory Jerome; Jessica E Teng; Patrick Ulysse; Louise C Ivers Journal: AIDS Res Ther Date: 2016-02-17 Impact factor: 2.250
Authors: Catherine A Koss; Paul Natureeba; Dorcas Nyafwono; Albert Plenty; Julia Mwesigwa; Bridget Nzarubara; Tamara D Clark; Theodore D Ruel; Jane Achan; Edwin D Charlebois; Deborah Cohan; Moses R Kamya; Diane V Havlir; Sera L Young Journal: J Acquir Immune Defic Syndr Date: 2016-03-01 Impact factor: 3.731
Authors: Kathleen Ridgeway; Lisa S Dulli; Kate R Murray; Hannah Silverstein; Leila Dal Santo; Patrick Olsen; Danielle Darrow de Mora; Donna R McCarraher Journal: PLoS One Date: 2018-01-02 Impact factor: 3.240
Authors: Zenaice Aloyce; Elysia Larson; Amina Komba; Angelina Mwimba; Anna Kaale; Anna Minja; Hellen Siril; Janeth Kamala; Magreat Somba; Fileuka Ngakongwa; Sylvia Kaaya; Mary C Smith Fawzi Journal: AIDS Care Date: 2020-08-03